Pilot-study: Predicton of response on Lu177-radioligand therapy in metastatic prostate carcinoma by early serial PSA-value examination - PCA-PSA-EPBR

Trial Profile

Pilot-study: Predicton of response on Lu177-radioligand therapy in metastatic prostate carcinoma by early serial PSA-value examination - PCA-PSA-EPBR

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs PSMA 617 (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms PCA-PSA-EPBR
  • Most Recent Events

    • 04 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top